Stocks Health care IMTX

NASDAQ · Health care

Immatics N.V. (IMTX)

It posted a net loss of €196.4M. In fiscal 2025 capital spending exceeded operating cash flow by €183.2M. At December 31, 2025 it held €345.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 5, 2026.

Watch IMTX in 60 seconds

Follow IMTX

Free, no password. An email when IMTX files with the SEC.

Key facts about Immatics N.V.

Net worth

Immatics N.V. has a market value (market cap) of $862.2M at the latest share price, and shareholders' equity of €484.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used €176.6M of cash.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 5, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What Immatics N.V. does

Immatics N.V. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IMTX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Immatics N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 26, 2026
   Foreign issuer update 6-K
2. October 23, 2026
   Foreign issuer update 6-K
3. August 27, 2026
   Activist stake changed SCHEDULE 13D/A
4. August 26, 2026
   Foreign issuer update 6-K
5. August 18, 2026
   Foreign issuer update 6-K
6. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
7. June 25, 2026
   Employee stock plan registration S-8
8. June 18, 2026
   Foreign issuer update 6-K
9. June 2, 2026
   Foreign issuer update 6-K
10. June 1, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 27, 2026. Insider transactions on SEC

Insider trades

What the people running Immatics N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $7.5M worth of shares on the open market in the last 90 days and sold none.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IMTX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Vestal Point Capital, LP 4.6% (May 15, 2026); Wellington Management Group LLP 4.4% (August 12, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 83 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 11,246,516 shares in total, about $72.3M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IMTX

What does Immatics N.V. do?

Immatics N.V. is a company in the Health care sector, listed on NASDAQ as IMTX. Its shares trade on NASDAQ under the ticker IMTX.

What is Immatics N.V.'s net worth?

Immatics N.V. has a market value (market cap) of $862.2M at the latest share price, and shareholders' equity of €484.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Immatics N.V. profitable?

No. In fiscal 2025 it reported a net loss of €196.4M.

When did Immatics N.V. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 5, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 26, 2026.

Similar companies

Compare IMTX with

Compare IMTX with any company

Follow IMTX

Get an email when Immatics N.V. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IMTX

Free, no password. An email when IMTX files with the SEC.

Where the numbers come from

Financial figures are the values Immatics N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.